Midas Letter

Sokoman Iron Corp (CVE:SIC) (OTCMKTS:GDNDF) (FRA:3PJ1) CEO Tim Froude discusses the company’s impressive assay results from their drilling at their Moosehead Gold Project in Central Newfoundland. The assay results have been received for the first three of fifteen holes and the results confirm a high-grade gold discovery in an area with little previous drilling. The news did not go unseen by investors, rising 760% in the 8 trading sessions following the discovery. The remaining twelve holes results are expected in the next few weeks and will be announced along with Sokoman Iron’s future programs.

James West:    Hey, welcome back to Midas Letter Live. My guest this segment is Tim Froude; he’s the CEO of Sokoman Iron Corp., trading on the TSX Venture under the symbol SIC. Tim, welcome to the show.

Tim Froude:    Thanks for having me, James.

James West:    Tim, it’s very seldom I get to talk to a gold exploration company that has increased in share price by 250 percent since a week. So tell me, how did you accomplish that?

Tim Froude:    Well, it was a very good drill hole that we drilled just in the recent couple of weeks, and obviously, yes, the market has responded quite favourably. Very high grade hole in a gold project out in

James E Wagner Cultivation Corporation (CVE:JWCA) (OTCMKTS:JWCAF) CEO Nathan Woodworth discusses receiving building permits for their large scale expansion project at their Kitchener facility. The expansion will facilitate JWC’s planned path to reduce cash cost per gram to below $1.00 through implementation of autonomous robotics and aeroponic production systems. JWC will eventually produce over 30,000 kilograms of cannabis flowers per year once the second facility is fully operational. The CEO also outlines Canopy Rivers Corporation’s significant ownership in JWC and participating in their craft grow program.

James West:    Hey there, welcome back to Midas Letter Live. My guest in this segment is Nathan Woodworth. He’s the CEO of James E. Wagner Cultivation Corporation, trading on the TSX Venture under the symbol JWCA. Nathan, welcome back.

Nathan Woodworth:   Hi James, thanks for having me.

James West:    Nathan, on July 26th, you entered into a collaboration agreement with Conestoga College in Kitchener. Could you elaborate on what exactly is the significance of that for your shareholders?

Nathan Woodworth:   Sure. Conestoga College is a really terrific technology school. They’ve got a lot of innovation going on there, and of course, at JWC we’re very big on innovation as well. So what we’re doing is getting together to look at some feasibility studies first to determine what types of technologies we will be collaborating on developing. And in just a couple of short months we’re hoping to launch into the first of those major projects.

One of the projects on the table, which I’m very excited about, is the implementation of autonomous robotics in our facilities. There are a lot of tasks which happen on a regul

Aurora Cannabis Inc (TSE:ACB) (OTCMKTS:ACBFF) (FRA:21P) CCO Cam Battley lists the catalysts that will drive value into Aurora’s share price going forward, and how Aurora shareholders will receive free Australis shares upon that company’s launch – anticipated in August

James West:    Hey, welcome to Midas Letter Live. My guest in this segment is none other than Cam Battley, Chief Corporate Officer for Aurora Cannabis Inc. Cam, welcome back.

Cam Battley:   Nice to see you, James.

James West:    Cam, you guys have been on fire in both directions, and it’s been very entertaining to watch.

Cam Battley:   That sounds actually pretty unhealthy.

James West:    Well, but, you know, burning the candle at both ends –

Cam Battley:   We’ve been very busy.

James West:    It articulates a brilliant lifestyle. So what’s happening with the MedReleaf takeover? Where are we at on all of that?

Cam Battley:   It’s going fast. Much faster than the CanniMed integration, and the CanniMed integration, I’m pleased to say, we got completed in the 90-day period. We have an amazing head of integration and a great integration team; our head of integration, Andre Jerome, ironically, we got him via acquisition, when we acquired a company in Lachute, Quebec called H2 Biopharma, which is soon to be our

Organigram Holdings Inc (CVE:OGI) (OTCMKTS:OGRMF) (FRA:0OG) CEO Greg Engel discusses their third quarter financial results and key factors which allow Organigram to be competitive with all cannabis corporations in the industry. Organigram are pursuing further supply agreements in Ontario, Nova Scotia, Newfoundland, and Saskatchewan in the near future as they get set for the start of the federally legalization of cannabis in Canada. Their expanding facilities, growing production capacity, and differentiated brands put them in a great position for the launch of the market.

James West:    Hey, welcome back to Midas Letter Live. My guest in this segment is Greg Engel. He’s the CEO of Organigram Holdings, trading on the TSX Venture under the symbol OGI. Greg, welcome back.

Greg Engel:    Thanks for having me again, James.

James West:    Greg, you just released third quarter results: give me an update, what do you think?

Greg Engel:    Well, a couple of key things. I mean, great quarter for us, and really some exciting things in there. I mean, I guess one of the keys would be that, you know, we continuously do our record yields; our cost of goods continue to come down. So, you know, our strategy as a major indoor producer or premium product has come forward and it’s been very well accepted in terms of preparing for the adult rec market, but at the same time w

48North Cannabis Corp (CVE:NRTH) (OTCMKTS:NCNNF) CEO Alison Gordon discusses their facility’s progress and differentiating plant genetics sourced from a Netherlands-based phyto-pharmaceutical company. The first female CEO of a Canadian cannabis corporation also provides her opinion and expertise on North American cannabis culture, the movement from flowers to consumer based goods, the cannabis preferences of the Millennial generation, and how Federal legalization will effect the black market.

James West:    My guest right now on this next segment is Alison Gordon is here. She’s the CEO of 48North Cannabis Company!

Alison Gordon: Thank you!

James West:    Thank you for coming today [laughter], Alison. It’s been what, two weeks since we’ve seen you?

Alison Gordon: I don’t know. Too long, too long.

James West:    Yeah, what’s new in the world of 48North Cannabis?

Alison Gordon: Lots is new. We were actually just out at the facility on Monday, and we are growing some amazing plants out there. It’s really exciting, actually. I told you last time that we had brought in genetics from the Netherlands, and those were being phenotyped. So going into the Mother room and seeing these amazing plants, I’m really excited for us to have some different genetics than everyone else out there.

James West:    Yeah.

Alison Gordon: So that’s super exciting. Always great to see it.

James West:    So what kind of genetics have you got, exactly?

Alison Gordon: Well, we’ve got 17 cultivars that we’ve brought in from seed from the Netherlands, so it’s a lot of different stuff. I won’t sit here and –

James West:

Namaste Technologies Inc (CVE:N) (OTCMKTS:NXTTF) (FRA:M5BQ) CEO Sean Dollinger discusses the evolution of the company – starting as an online U.S. vape vendor and becoming one of the largest global consumer cannabis retailers soon to be listed on the NASDAQ stock market. The CEO describes their online telemedicine app, Namaste MD, where patients can connect with nurse practitioners and receive cannabis products delivered to their door. He also discusses future Namaste developments using AI and machine learning portals inside the cannabis space.

James West:    Hey, welcome back to Midas Letter Live. My guest this segment is Sean Dollinger, President and CEO of Namaste Technologies. Sean, welcome back.

Sean Dollinger:     Thank you very much for having us.

James West:    Sean, your company never ceases to surprise me, and again you’ve done it: you’re moving to the NASDAQ. Like, that’s incredible.

Sean Dollinger:     Yeah, it’s a great accomplishment. We went ahead and announced it earlier in the week. We’ve met all the criteria as you know; we have our live show once a week on Namaste 420.

James West:    I’ve watched it.

Sean Dollinger:     And, you know, on there, we went ahead a couple months back and said we’d do everything in our power to get qualified for it. The one thing that we left up to our

Faircourt Asset Management President Charles Taerk picks Aphria Inc (TSE:APH | OTCMKTS:APHQF | FRA:10E) as one of his current favourite cannabis plays. The company’s executive team, production efficiency, as well as their Canadian and international expansion capacity are all discussed. Smaller investment opportunities are also highlighted looking for the largest growth opportunities as Canadian legalization quickly approaches.

James West:    Hey, welcome back to Midas Letter RAW! My guest, you might recognize him; he seems to have become a regular on the show. Charles Taerk is the co-manager? Manager, of the Ninepoint UIT Alternative Health Fund.

Charles Taerk: Well, good for you.

James West:    Thank you.

Charles Taerk: It’s a team effort; Doug Waters and myself.

James West:    I like that. Right, right, okay. So anyways, but you are one of the only institutional choices in terms of an active manager that is, you know, buying cannabis stocks.

Charles Taerk: That’s correct.

James West:    And let’s touch quickly on, why would I invest in your fund in terms of performance?

Charles Taerk: Well, great. Year-to-date, we’re doing quite well; year-to-date we’re up close to 10 percent relative to the index or the large ETFs, which I think are still negative for the year. We’re an actively mana

CannaRoyalty Corp (CNSX:CRZ) (OTCMKTS:CNNRF) (FRA:CY4) CEO Mark Lustig discusses the company’s growing portfolio of investments and their valuation relative to competitors in the industry. The CEO details their recent $30m private placement, Aurora Cannabis Inc’s (TSE:ACB) (OTCQB:ACBFF) (FRA:21P) acquisition of their pre-roll technology and Anadia Labs, as well as the prevalence of their products in Californian dispensaries.

James West:    Hey, welcome back to Midas Letter Live. My guest in this segment is Marc Lustig; he’s with CannaRoyalty Corp, CSE-listed CRZ. Marc, welcome back.

Marc Lustig:   Thanks for having me.

James West:    Marc, CannaRoyalty has been knocking it out of the park by all accounts. The value of your portfolio of investments keeps going up, your share price is, I’m sure, putting smiles on a lot of faces relative to what’s going on in the sector. You’ve really started to make this solid move as an operator in California, and you recently closed a $30 million private placement. Is that to support that sort of ongoing evolution of the company?

Ma

Canaccord Genuity Group Analyst Matt Bottomley sees Aurora Cannabis Inc (TSX:ACB) (OTCQB:ACBFF) (FRA:21P) at $11 a share, according to research he published last week citing “the coming together of two industry giants”. He suggests “After consolidating MedReleaf into our model, our FY2019 revenue forecast increases to $512M (from $336M) and EBITDA increases to $171M (from $114M).”

Transcript:

James West:    Hey there, welcome back to Midas Letter Live. My guest in this segment is Matt Bottomley, who’s been here a few times before. He’s the equity analyst at Canaccord Genuity. Matt, welcome back.

Matt Bottomley: Good to see you again, James.

James West:    Matt, you recently published on Aurora Cannabis, and kind of a timely story in that they’ve just completed their merger with MedReleaf.

Matt Bottomley: Right. So yeah, I mean, this has been a deal that was announced maybe a month or two ago, so it’s been a long time coming, I think. I think M&A is to be expected in this space, and now we’ve combined arguably by infrastructure built and some other metrics, probably the number two and the number four name in the space by size into what could be the largest entity, now. So currently, Canopy and Aurora are certainly the leaders by market cap and many other metrics.

James West:    Okay. So is Aurora now the biggest by market cap than even Canopy? Or are they more or less at the same level?

Matt Bottomley: Well, I mean, they’re trading at similar levels right now. Canopy is trading a bit higher on an absolute basis, but I think if you look at the recreational market, potential brand awareness – although branding is going to be quite challenging for all these LPs – how many provinces LPs are in, built infrastructure, Canopy is definitely the largest company in the market. But I think that when you look at the medical side of things, we have Aurora that’s, I think, acquired two of the top three names in the space when it comes to medical, that being CanniMed, now MedReleaf. I believe CannTrust is another quality name, as well.

So I’m not forecasting any future M&A on that front when it comes to what Aurora might be doing on its medical side, but I think they clearly have the number one spot by size and scale, and potentially expertise, when it comes to the medical side of things – which is likely going to get higher pricing over the long term in terms of retail pricing. It’s likely going to have a very compelling growth profile as well. I think we’re probably only 30, 40 percent ramped up of our medical patient base in Canada. And when it comes to the international opportunity, which a lot of these LPs are getting into, Aurora is still a top three name when it comes to international exposure, and with medical expertise – because remember, all these international markets are medical – they might ha

Aurora Cannabis Inc (TSX:ACB) (OTCQB:ACBFF) (FRA:21P) is expected to hit $11 a share again, according toCanaccord Genuity Group Analyst Matt Bottomley. He published last week citing “the coming together of two industry giants”. He suggests “After consolidating MedReleaf into our model, our FY2019 revenue forecast increases to $512M (from $336M) and EBITDA increases to $171M (from $114M).”

Transcript:

James West:    Hey there, welcome back to Midas Letter Live. My guest in this segment is Matt Bottomley, who’s been here a few times before. He’s the equity analyst at Canaccord Genuity. Matt, welcome back.

Matt Bottomley: Good to see you again, James.

James West:    Matt, you recently published on Aurora Cannabis, and kind of a timely story in that they’ve just completed their merger with MedReleaf. So that puts 386 million MedReleaf shares in the wind, so to speak.

Matt Bottomley: Right. So yeah, I mean, this has been a deal that was announced maybe a month or two ago, so it’s been a long time coming, I think. I think M&A is to be expected in this space, and now we’ve combined arguably by infrastructure built and some other metrics, probably the number two and the number four name in the space by size into what could be the largest entity, now. So currently, Canopy and Aurora are certainly the leaders by market cap and many other metrics.

James West:    Okay. So is Aurora now the biggest by market cap than even Canopy? Or are they more or less at the same level?

Matt Bottomley: Well, I mean, they’re trading at similar levels right now. Canopy is trading a bit higher on an absolute basis, but I think if you look at the recreational market, potential brand awareness – although branding is going to be quite challenging for all these LPs – how many provinces LPs are in, built infrastructure, Canopy is definitely the largest company in the market. But I think that when you look at the medical side of things, we have Aurora that’s, I think, acquired two of the top three names in the space when it comes to medical, that being CanniMed, now MedReleaf. I believe CannTrust is another quality name, as well.

So I’m not forecasting any future M&A on that front when it comes to what Aurora might be doing on its medical side, but I think they clearly have the number one spot by size and scale, and potentially expertise, when it comes to the medical side of things – which is likely going to get higher pricing over the long term in terms of retail pricing. It’s likely going to have a very compelling growth profile as well. I think we’re probably only 30, 40 percent ramped up of our medical patient base in Canada. And when it comes to the international opportunity, which a lot of these LPs are getting into, Aurora is still a top three name when it comes to international exposure, and with medical expertise – b